Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Viatris Snaps Up Japan’s Aculys Pharma, Gains 2 CNS Assets
US-based Viatris said on October 15 that it has acquired Tokyo biotech Aculys Pharma, gaining two central nervous system (CNS) assets that will strengthen its presence in the Japanese market. Through the acquisition, Viatris obtains the exclusive development and commercialization…
To read the full story
Related Article
- Aculys Rolls Out Spydia Nasal Spray in Japan
December 25, 2025
- Aculys Moves Toward First Launch as It Tackles Japan’s Drug Lag/Loss
June 24, 2025
BUSINESS
- Amvuttra Key to Alnylam Japan’s 25%-Plus CAGR Goal through 2030
August 20, 2026
- Biogen Japan President Den Tapped as Chief of Staff to Global CEO
August 20, 2026
- Moderna’s mNEXSPIKE Grabs Japan Approval for XFG Variant
August 20, 2026
- Nipro’s Forxiga AG to Hit Shelves on September 4
August 20, 2026
- Teijin Taps CAR-T Expert Campana as Technical Advisor
August 20, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…